BMI, depressive symptoms, and fatigue scores at postpartum follow-ups by sleep trajectory class.

<p>^a Effect size, based on comparison with class 1.</p><p>^b All analyses were adjusted for baseline age and parity.</p><p>^c Linear regression with class 1 coded as 1, class 2 coded as 2, and class 3 coded as 3.</p><p>BMI, body mass index; EPDS, Edinburgh Postnatal Depression Scale; FCF, Fatigue Continuum Form.</p><p>BMI, depressive symptoms, and fatigue scores at postpartum follow-ups by sleep trajectory class.</p

PSQI component scores and sleep variables at each assessment.

<p>PSQI, Pittsburgh Sleep Quality Index.</p><p>PSQI component scores and sleep variables at each assessment.</p

Three classes of sleep trajectories from third-trimester pregnancy to 6 months after cesarean delivery (<i>N</i> = 139).

<p>Class 1 (stable poor sleep; 36.0%), class 2 (progressively worse sleep; 48.2%), and class 3 (persistently poor sleep; 15.8%).</p

Comparison of baseline characteristics among sleep trajectories classes (n = 139).

<p>^a Fisher’s exact test</p><p>PCA, Patient-controlled analgesia; BMI, body mass index; EPDS, Edinburgh Postnatal Depression Scale; FCF, Fatigue Continuum Form.</p><p>Comparison of baseline characteristics among sleep trajectories classes (n = 139).</p

Trajectories of sleep components from third-trimester pregnancy to 6 months post-cesarean delivery (<i>N</i> = 139).

<p><b>A:</b> sleep at night (hours); <b>B:</b> sleep onset latency (minutes); <b>C:</b> sleep efficiency (%), and <b>D:</b> insomnia (%).</p

Nonplanar Aromatic Compounds. 5. A Strategy for the Synthesis of <i>cis</i>-10b,10c-Dimethyl-10b,10c-dihydropyrenes. First Crystal Structure of a <i>cis</i>-10b,10c-Dimethyl-10b,10c-dihydropyrene

Through the use of a potentially removable tether, a heavily substituted 10b,10c-dimethyl-10b,10c-dihydropyrene (DMDHP), 20, was synthesized exclusively as the cis-isomer. It exists as the major component (20:1) in an equilibrium with its valence isomer syn-[2.2]metacyclophanediene 19. An X-ray crystal structure determination of 20, a cis-(2,7)-10b,10c-dihydropyrenophane, provided the first experimental measurements of the cis-DMDHP skeleton. The observed bond alternation in the [14]annulene was found to be larger than that of the corresponding trans-DMDHP framework. Prior MMPI calculations, on which previous discussion of the structure of the cis-DMDHP system had been based, are in very good agreement with the experimental results. Our own DFT calculations predict a more symmetric and more bond equalized structure than was observed in 20

Nonplanar Aromatic Compounds. 5. A Strategy for the Synthesis of <i>cis</i>-10b,10c-Dimethyl-10b,10c-dihydropyrenes. First Crystal Structure of a <i>cis</i>-10b,10c-Dimethyl-10b,10c-dihydropyrene

Through the use of a potentially removable tether, a heavily substituted 10b,10c-dimethyl-10b,10c-dihydropyrene (DMDHP), 20, was synthesized exclusively as the cis-isomer. It exists as the major component (20:1) in an equilibrium with its valence isomer syn-[2.2]metacyclophanediene 19. An X-ray crystal structure determination of 20, a cis-(2,7)-10b,10c-dihydropyrenophane, provided the first experimental measurements of the cis-DMDHP skeleton. The observed bond alternation in the [14]annulene was found to be larger than that of the corresponding trans-DMDHP framework. Prior MMPI calculations, on which previous discussion of the structure of the cis-DMDHP system had been based, are in very good agreement with the experimental results. Our own DFT calculations predict a more symmetric and more bond equalized structure than was observed in 20

Table3_The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.XLSX

Esophageal cancer (EC) remains a leading cause of death worldwide and in Taiwan. The prognosis of advanced-stage EC is notably poor, and the treatment options are limited. Chinese herbal medicine (CHM) has been widely used as a complementary treatment for cancer, yet the long-term effect of CHM in stage IV EC remains unclear.The multi-institutional cohort obtained from the Chang Gung research database (CGRD) was used to study the long-term outcome of CHM use among incident stage IV EC patients from 1 January 2002, to 31 December 2018. All patients were followed up to 5 years or the occurrence of death. The overall survival (OS) and disease-specific survival rates were conducted using Kaplan-Meier estimation. Overlap weighing and landmark analysis were used to eliminate confounding and immortal time biases. Furthermore, we demonstrated the core CHMs for stage IV EC by using the Chinese herbal medicine network (CMN) analysis on prescriptions.Nine hundred eighty-five stage IV EC patients were analyzed, including 74 CHM users and 911 non-CHM users. We found the use of CHM was associated with a higher 5-year overall survival rate than CHM nonusers (the cumulative probability: 19.52% versus 6.04%, log-rank test: p The use of CHM seems safe and possibly beneficial among stage IV EC patients with a higher 5-year OS. Further clinical trials on CHM were guaranteed to explore the role of CHM in managing stage IV EC patients.</p

Table4_The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.XLSX

Esophageal cancer (EC) remains a leading cause of death worldwide and in Taiwan. The prognosis of advanced-stage EC is notably poor, and the treatment options are limited. Chinese herbal medicine (CHM) has been widely used as a complementary treatment for cancer, yet the long-term effect of CHM in stage IV EC remains unclear.The multi-institutional cohort obtained from the Chang Gung research database (CGRD) was used to study the long-term outcome of CHM use among incident stage IV EC patients from 1 January 2002, to 31 December 2018. All patients were followed up to 5 years or the occurrence of death. The overall survival (OS) and disease-specific survival rates were conducted using Kaplan-Meier estimation. Overlap weighing and landmark analysis were used to eliminate confounding and immortal time biases. Furthermore, we demonstrated the core CHMs for stage IV EC by using the Chinese herbal medicine network (CMN) analysis on prescriptions.Nine hundred eighty-five stage IV EC patients were analyzed, including 74 CHM users and 911 non-CHM users. We found the use of CHM was associated with a higher 5-year overall survival rate than CHM nonusers (the cumulative probability: 19.52% versus 6.04%, log-rank test: p The use of CHM seems safe and possibly beneficial among stage IV EC patients with a higher 5-year OS. Further clinical trials on CHM were guaranteed to explore the role of CHM in managing stage IV EC patients.</p

Table1_The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.DOCX

Esophageal cancer (EC) remains a leading cause of death worldwide and in Taiwan. The prognosis of advanced-stage EC is notably poor, and the treatment options are limited. Chinese herbal medicine (CHM) has been widely used as a complementary treatment for cancer, yet the long-term effect of CHM in stage IV EC remains unclear.The multi-institutional cohort obtained from the Chang Gung research database (CGRD) was used to study the long-term outcome of CHM use among incident stage IV EC patients from 1 January 2002, to 31 December 2018. All patients were followed up to 5 years or the occurrence of death. The overall survival (OS) and disease-specific survival rates were conducted using Kaplan-Meier estimation. Overlap weighing and landmark analysis were used to eliminate confounding and immortal time biases. Furthermore, we demonstrated the core CHMs for stage IV EC by using the Chinese herbal medicine network (CMN) analysis on prescriptions.Nine hundred eighty-five stage IV EC patients were analyzed, including 74 CHM users and 911 non-CHM users. We found the use of CHM was associated with a higher 5-year overall survival rate than CHM nonusers (the cumulative probability: 19.52% versus 6.04%, log-rank test: p The use of CHM seems safe and possibly beneficial among stage IV EC patients with a higher 5-year OS. Further clinical trials on CHM were guaranteed to explore the role of CHM in managing stage IV EC patients.</p